International Assets Investment Management LLC Has $36.06 Million Stock Position in Veeva Systems Inc. (NYSE:VEEV)

International Assets Investment Management LLC raised its holdings in shares of Veeva Systems Inc. (NYSE:VEEV) by 16,580.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 187,322 shares of the technology company’s stock after buying an additional 186,199 shares during the quarter. International Assets Investment Management LLC’s holdings in Veeva Systems were worth $36,063,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. LA Financiere DE L Echiquier grew its position in Veeva Systems by 24.4% during the fourth quarter. LA Financiere DE L Echiquier now owns 63,479 shares of the technology company’s stock worth $12,221,000 after buying an additional 12,461 shares in the last quarter. Valley National Advisers Inc. lifted its position in shares of Veeva Systems by 22.5% in the 4th quarter. Valley National Advisers Inc. now owns 1,224 shares of the technology company’s stock worth $235,000 after acquiring an additional 225 shares during the period. Investment Partners Asset Management Inc. acquired a new stake in shares of Veeva Systems during the 4th quarter worth approximately $238,000. Nisa Investment Advisors LLC increased its position in shares of Veeva Systems by 43.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 31,517 shares of the technology company’s stock valued at $6,068,000 after purchasing an additional 9,490 shares during the period. Finally, Lannebo Fonder AB raised its stake in shares of Veeva Systems by 16.9% in the fourth quarter. Lannebo Fonder AB now owns 170,287 shares of the technology company’s stock valued at $33,347,000 after purchasing an additional 24,600 shares in the last quarter. 88.20% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Jonathan Faddis sold 3,598 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $207.42, for a total value of $746,297.16. Following the transaction, the senior vice president now owns 10,668 shares in the company, valued at $2,212,756.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, SVP Jonathan Faddis sold 3,598 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $207.42, for a total transaction of $746,297.16. Following the completion of the sale, the senior vice president now directly owns 10,668 shares of the company’s stock, valued at $2,212,756.56. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Timothy S. Cabral sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $226.04, for a total transaction of $3,390,600.00. Following the completion of the transaction, the director now directly owns 23,391 shares in the company, valued at $5,287,301.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,989 shares of company stock valued at $4,818,013. 10.98% of the stock is currently owned by corporate insiders.

Veeva Systems Stock Performance

Shares of NYSE:VEEV opened at $203.49 on Friday. The business has a fifty day moving average of $217.75 and a 200-day moving average of $202.20. The firm has a market cap of $32.83 billion, a PE ratio of 63.18, a price-to-earnings-growth ratio of 2.01 and a beta of 0.76. Veeva Systems Inc. has a twelve month low of $160.21 and a twelve month high of $236.90.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings data on Thursday, February 29th. The technology company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.11. Veeva Systems had a net margin of 22.24% and a return on equity of 11.26%. The firm had revenue of $630.62 million during the quarter, compared to analysts’ expectations of $620.75 million. On average, analysts anticipate that Veeva Systems Inc. will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

VEEV has been the topic of a number of recent research reports. Robert W. Baird lifted their price target on shares of Veeva Systems from $245.00 to $251.00 and gave the stock an “outperform” rating in a research note on Friday, March 1st. Jefferies Financial Group lifted their target price on shares of Veeva Systems from $225.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Stifel Nicolaus increased their price target on shares of Veeva Systems from $205.00 to $250.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $250.00 price objective on shares of Veeva Systems in a report on Wednesday, March 27th. Finally, KeyCorp upped their price objective on Veeva Systems from $232.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, March 5th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $234.90.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.